What is Corvia Medical?
Corvia Medical is a specialized medical device enterprise dedicated to the development of novel transcatheter cardiovascular solutions. The company focuses on addressing the complex challenges associated with heart failure, particularly for patient populations where traditional therapeutic options remain limited. By engineering minimally invasive devices, Corvia Medical aims to improve hemodynamic outcomes and enhance the quality of life for patients, effectively bridging the gap between pharmaceutical management and invasive surgical interventions. Its market position is defined by a commitment to rigorous clinical validation and the pursuit of disruptive science in the cardiovascular space.
How much funding has Corvia Medical raised?
Corvia Medical has raised a total of $168.1M across 6 funding rounds:
Series A
$5.4M
Series B
$9M
Series C
$10.7M
Series D
$34M
Unspecified
$54M
Other Financing Round
$55M
Series A (2009): $5.4M, investors not publicly disclosed
Series B (2012): $9M, investors not publicly disclosed
Series C (2013): $10.7M supported by Lumira Ventures, General Catalyst, and Third Rock Ventures
Series D (2014): $34M featuring ACCELMED, Lumira Ventures, General Catalyst, and Third Rock Ventures
Unspecified (2022): $54M, investors not publicly disclosed
Other Financing Round (2025): $55M with participation from General Catalyst, Accelmed, Third Rock Ventures, and Lumira Capital
Key Investors in Corvia Medical
General Catalyst
General Catalyst is a prominent venture capital firm that partners with founders to build enduring enterprises, providing both strategic capital and operational expertise across the healthcare and technology sectors.
Third Rock Ventures
Third Rock Ventures is a specialized healthcare firm focused on discovering and launching disruptive companies in science and medicine to create meaningful improvements in patient outcomes.
Lumira Ventures
Lumira Ventures is a leading life sciences venture capital firm that invests in healthcare innovators, supporting the development of impactful medical devices and biotherapeutics.
What's next for Corvia Medical?
With the successful closure of this latest financing round, Corvia Medical is well-positioned to accelerate its commercialization strategy and expand its clinical footprint. The influx of capital will likely be directed toward scaling manufacturing capabilities, supporting ongoing clinical trials, and navigating the regulatory pathways necessary for broader market adoption. As the company moves into this next phase of maturity, the focus will shift toward establishing long-term market dominance and demonstrating the sustained clinical efficacy of its transcatheter platform. The continued involvement of its core investor syndicate provides not only the necessary financial runway but also the strategic guidance required to navigate the complexities of the global medical technology landscape.
See full Corvia Medical company page
